MISSISSAUGA, Ontario–(BUSINESS WIRE)–VIQ Solutions Inc. (“VIQ”, “VIQ Solutions” or the “Company”) (TSX: VQS), a global provider of secure, AI-driven, digital voice and video capture technology and transcription services, announced the voting results from its annual general meeting of shareholders (the “Meeting”) on June 13, 2025. Shareholders approved all matters set forth in the Company’s management … [Read more…]
Inclusion of experts, patient voices, and equity-focused policy reflects priorities long championed by Breast Cancer Canada TORONTO–(BUSINESS WIRE)–Breast Cancer Canada proudly celebrates the federal government’s response to the External Expert Review (EER) of the Canadian Task Force on Preventive Health Care, and the sweeping reforms it recommends to ensure preventive health guidance in Canada is … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Messenger RNA Market – A Global and Regional Analysis: Focus on Application and Regional Analysis – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global messenger RNA market is currently in the growth stage of its lifecycle, driven by the rapid success of mRNA vaccines, particularly for COVID-19, which … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “High Throughput Process Development – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for High Throughput Process Development was valued at US$15.3 Billion in 2024 and is projected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This comprehensive report … [Read more…]
Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® … [Read more…]
Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg® Independent dataset from EAP reinforces the findings from the pivotal ARES trial and has also been included in the EMA Marketing Authorization Application submitted on June 2nd, 2025 EAP for Xervyteg® in aGvHD is … [Read more…]
Preclinical data from IPH6501, Innate’s proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL … [Read more…]
Intends to file definitive proxy materials in the coming days BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of … [Read more…]
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free … [Read more…]
BARCELONA, Spain–(BUSINESS WIRE)–Hospital for Special Surgery (HSS) presented new findings at the European Alliance of Associations for Rheumatology (EULAR) Annual Meeting that could help pave the way for more personalized treatment for people with rheumatoid arthritis (RA) by analyzing the cellular composition of synovial fluid inside their joints. RA is a chronic disease characterized by … [Read more…]
